Inclusion Criteria

Criteria:

- Adenocarcinoma of the gallbladder

- Recurrent extrahepatic bile duct cancer

- Recurrent gallbladder cancer

- Unresectable extrahepatic bile duct cancer

- Adenocarcinoma of the extrahepatic bile duct

- Unresectable gallbladder cancer

- Prior surgery and radiotherapy allowed

- At least 28 days since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)
and recovered

- No other concurrent investigational agents, chemotherapy, radiotherapy, or hormonal
therapy

- Concurrent hormones administered for nondisease-related conditions (e.g., insulin for
diabetes) allowed

- No concurrent corticosteroids or anticonvulsants

- Concurrent steroids administered for antiemesis, adrenal failure, or septic shock
allowed

- No concurrent combination antiretroviral therapy for HIV-positive patients

- Histologically or cytologically confirmed adenocarcinoma of the gallbladder or bile
duct, meeting all of the following criteria: locally advanced or metastatic disease
that is unresectable

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
conventional techniques or >= 10 mm by spiral CT scan

- Tumor that recurs within a previously irradiated field is considered measurable
disease if recurrence is documented and measurable by RECIST criteria

- Tumor must be Her2/neu positive by FISH testing

- No symptomatic brain metastases

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- ANC >= 1,500/mm^3

- Fertile patients must use effective contraception prior to, during, and for >= 3
months after completion of study treatment

- Creatinine =< 2 times ULN OR creatinine clearance >= 60 mL/min

- No other active malignancy

- LVEF >= 50%

- No concurrent uncontrolled illness

- No ongoing or active infection requiring systemic IV antibiotics on day 1 of
treatment

- No symptomatic New York Heart Association class III-IV congestive heart failure

- No unstable angina pectoris

- No unstable cardiac arrhythmia requiring medication

- No more than 1 prior systemic chemotherapy regimen

- WBC >= 3,000/mm^3

- Platelet count >= 40,000/mm^3

- Bilirubin =< 4 mg/dL

- AST and ALT =< 5 times upper limit of normal (ULN)

- Not pregnant or nursing

- Negative pregnancy test